Author [ Title] Type Year
Filters: Author is Gertz, Morie A [Clear All Filters]
Autologous stem cell transplant for AL amyloidosis patients aged 70 to 75. Biol Blood Marrow Transplant. 2018.
Autologous stem cell transplantation in immunoglobulin light chain amyloidosis with factor X deficiency. Blood Coagul Fibrinolysis. 2015.
Immunoglobulin Light-Chain Amyloidosis: From Basics to New Developments in Diagnosis, Prognosis and Therapy. Acta Haematol. 2016;135(3):172-190..
Immunoparesis status in AL amyloidosis at diagnosis affects response and survival by regimen type. Haematologica. 2016.
Long-term disease control in patients with newly diagnosed multiple myeloma after suspension of lenalidomide therapy. Am J Hematol. 2013.
Multiple Myeloma in the Time of COVID-19. Acta Haematol. 2020:1-7..
Outcomes of patients with renal monoclonal immunoglobulin deposition disease. Am J Hematol. 2016.
Prognostic restaging at the time of second-line therapy in patients with AL amyloidosis. Leukemia. 2019.
Prognostic Role of Beta-2 Microglobulin in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation. Biol Blood Marrow Transplant. 2020.
Systemic Amyloidosis Recognition, Prognosis, and Therapy: A Systematic Review. JAMA. 2020;324(1):79-89..
Trends and Outcomes in Allogeneic Hematopoietic Stem Cell Transplant for Multiple Myeloma at Mayo Clinic. Clin Lymphoma Myeloma Leuk. 2015.